Table 3.
Radiological findings of discharged patients.
| RP patients |
NRP patients |
|||||||
|---|---|---|---|---|---|---|---|---|
| 14 days after discharge (n = 32) | 28 days after discharge (n = 32) | 3 months after discharge (n = 18) | 6 months after discharge (n = 3) | 14 days after discharge (n = 420) | 28 days after discharge (n = 396) | 3 months after discharge (n = 245) | 6 months after discharge (n = 93) | |
| Inflammation absorption | 16 (50%) | 9 (28.1%) | 6 (33.3%) | 1 (33.3%) | 270(64.3%) | 181 (45.7%) | 75 (30.6%) | 16 (17.2%) |
| No obvious abnormality | 7 (21.9%) | 14 (43.8%) | 8 (44.4%) | 1 (33.3%) | 85 (20.2%) | 102 (25.8%) | 67 (27.3%) | 25 (26.9%) |
| Ground-glass opacity | 2 (6.3%) | 2 (6.3%) | 2 (11.1%) | 0 (0%) | 36 (8.6%) | 28 (6.3%) | 8 (3.3%) | 5 (5.4%) |
| Consolidation | 1 (3.1%) | 1 (3.1%) | 1 (5.6%) | 0 (0%) | 40 (9.5%) | 47 (11.9%) | 46 (18.8%) | 24 (25.8%) |
| Nodular shadowing | 3 (9.4%) | 4 (12.5%) | 2 (11.1%) | 0 (0%) | 51 (12.1%) | 55 (13.9%) | 39 (15.9%) | 15 (16.1%) |
| Pleural incrassation | 3 (9.4%) | 3 (9.4%) | 0 (0%) | 0 (0%) | 31 (7.4%) | 32 (8.1%) | 28 (11.4%) | 9 (9.7%) |
| Emphysema/Pulmonary bulla | 1 (3.1%) | 1 (3.1%) | 0 (0%) | 0 (0%) | 16 (3.8%) | 18 (4.5%) | 12 (4.9%) | 8 (8.6%) |
| Enhanced lung marking | 3 (9.4%) | 1 (3.1%) | 1 (5.6%) | 1 (33.3%) | 7 (1.7%) | 9 (2.3%) | 16 (6.5%) | 4 (4.3%) |
Data are presented as the n (n/N%), where N denotes the total number of patients for whom data were available.
RP, re-detectable positive; NRP, no re-detectable positive.